How do these compounds compare to semaglutide
MSDC-0602K has shown substantial decreases in glucose, insulin, liver enzymes, and the non-alcoholic fatty liver disease activity score (NAS) in patients with biopsy-confirmed MASH and fibrosis (F1-F3) with minimal side effects, 21 prompting a phase 3 study to assess the benefits of MSDC-0602K on glycemic control and cardiovascular outcomes in patients with pre-T2D or T2D and MASLD/MASH (NCT03970031)
Weight loss alone accounts for significant mental health improvements, with studies showing self-esteem increases of up to 131% following substantial weight reduction
Severe or continuing vomiting and diarrhea may lead to dehydration and possible kidney problems
Then tirzepatide arrived and raised the bar, adding a second receptor target and delivering results that made semaglutide look modest by comparison
Always ensure you are rotating sites and using a fresh needle to minimize these risks